Drug intelligence / Profile preview

DW51211

Development stage: Unknown
Lead developer: Daewon Pharm
Administration: Oral

Overview

DW51211 is an experimental pharmaceutical agent investigated as a comparator (control) drug in a Phase 3 clinical trial for the treatment of acute bronchitis, conducted alongside DW5121 and DW51212. In the referenced study, DW51211 was administered orally, three times a day for 7 days, to evaluate its efficacy and safety based on changes in the Bronchitis Severity Score (BSS), but no details regarding its composition, mechanism of action, or pharmacological class are disclosed in the available public trial records[1][2][4].

Other names: DW51211DW-51211DW 51211

Beyond the preview

Go deeper on DW51211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW51211.

Explore the full profile